DiaMedica Therapeutics Highlights Clinical Gains Amid Trial Risks

Diamedica Therapeutics ((DMAC)) has held its Q4 earnings call. Read on for the main highlights of the call.

DiaMedica Therapeutics’ latest earnings call struck a cautiously optimistic tone as management highlighted strong clinical signals in preeclampsia, solid progress in its ReMEDy2 stroke program and an extended cash runway into 2027. At the same time, rising operating expenses, a complicated reproductive toxicology request from the FDA and potential stroke trial expansion tempered enthusiasm with clear regulatory and cost risks.

Robust Blood Pressure and Perfusion Data in Preeclampsia

Interim Part 1a data from investigator‑sponsored Phase II cohorts 6–9 in preeclampsia showed statistically significant, dose‑dependent and sustained reductions in both systolic and diastolic blood pressure. The study also reported significant reductions in uterine artery pulsatility index, an indicator of improved uteroplacental perfusion, suggesting DM199 may meaningfully stabilize maternal hemodynamics.

Encouraging Safety Profile Supports Earlier, Longer Treatment

DM199 was not detected crossing the placental barrier or in breast milk in the reported patients, indicating a maternal‑only exposure profile. Management emphasized that this safety signal could enable earlier initiation and longer treatment duration with the goal of prolonging pregnancy and improving outcomes in a high‑risk obstetric population.

Regulatory Momentum for Early‑Onset Preeclampsia Program

DiaMedica secured Health Canada clearance for a global Phase II trial in early‑onset preeclampsia, designed as an open‑label, dose‑finding study in about 30 patients across three dose levels. The company aims to complete a Part 1a expansion cohort of up to 12 additional patients in the first half of 2026 while finalizing Part 1b and Part 2 protocols and targeting broader site activations, including in the U.K., in the second half of 2026.

Pipeline Expansion into Fetal Growth Restriction

Beyond classical preeclampsia, management plans to explore DM199 in a cohort of patients with fetal growth restriction, with first dosing expected in the second quarter of 2026. This strategy could extend the asset’s reach into another severe pregnancy complication where improved uteroplacental blood flow may be clinically meaningful.

ReMEDy2 Stroke Trial Builds Enrollment Momentum

The ReMEDy2 ischemic stroke trial is gaining traction, having achieved almost 70% of the 200 participants needed for the interim analysis, implying roughly 140 enrolled. About 61 sites are currently active, including four in the U.K. and 12 in Europe, and management expects approximately 25 additional sites to come online in the near term to further accelerate recruitment.

DSMB Safety Green Light in Stroke Study

An independent Data Safety Monitoring Board reviewed safety data after 100 patients in ReMEDy2 and unanimously recommended that the trial continue without modification. This endorsement reduces near‑term safety risk and supports management’s guidance that the interim analysis remains on track for the second half of 2026, assuming enrollment continues at the improved pace.

Scientific Validation via Hypertension Publication

A new paper in the Journal of Hypertension outlined DiaMedica’s “Endothelial Triple Pathway” strategy and referenced prior Phase II REDUX results. Those data showed that DM199 can significantly reduce blood pressure over three months and lower serum potassium in patients with elevated levels, reinforcing its potential relevance in resistant hypertension and chronic kidney disease.

Strengthened Balance Sheet Extends Cash Runway

As of Dec. 31, 2025, DiaMedica held $59.9 million in cash, cash equivalents and short‑term investments, up from $44.1 million a year earlier, with working capital rising to $55.5 million. Management believes this improved liquidity, supported by a 2025 private placement and at‑the‑market program, can fund planned trials and operations through the end of 2027.

Operating Cash Burn and Expenses Trend Higher

Net cash used in operating activities climbed to $29.1 million in 2025 from $22.1 million in 2024, reflecting a near‑32% increase. Research and development expenses rose to $24.6 million while general and administrative costs reached $9.8 million, driven by global trial expansion, increased clinical staffing and higher non‑cash share‑based compensation and corporate costs.

FDA Reproductive Toxicology Request Adds Regulatory Overhang

The FDA requested an additional reproductive toxicology study in rabbits, but recent dose‑range findings suggest rabbits mount an unusual immune response to recombinant human DM199, making them an unreliable model. While prior studies in roughly 200 offspring showed no teratogenic effects, DiaMedica must now identify an alternative species and negotiate a path forward with regulators, creating timing uncertainty for its U.S. program.

Site‑Level Staffing Issues Slow Preeclampsia Enrollment

Enrollment in the Part 1a preeclampsia expansion cohort lagged expectations due to staffing constraints at the lead South African site. The company has provided financial support and reported new nursing hires, and it now forecasts completion of this expansion in the second quarter of 2026, a modest operational delay but one management believes is now being addressed.

Stroke Trial Could Become Larger and More Expensive

The upcoming interim analysis in ReMEDy2 includes a futility check and allows for sample‑size re‑estimation up to a range of 300 to 728 patients. Management’s base case assumes roughly 300–350 participants if the effect size mirrors prior Phase II results, but any need to push beyond 500 patients would force a reassessment of program priorities and capital allocation.

Uncertain Timeline for U.S. IND Advancement

DiaMedica is still working with the FDA to agree on acceptable nonclinical models, and management declined to offer a definitive timeline for regulatory alignment. This adds a layer of uncertainty around the start of U.S. trials, even as the company advances its clinical plans in Canada and other jurisdictions where regulatory pathways appear clearer.

Guidance Underscores Clinical Milestones and Runway

Management reaffirmed that its $59.9 million cash position and $55.5 million of working capital should support operations through the end of 2027, despite 2025 operating cash use of $29.1 million. Key milestones include completing the ReMEDy2 interim analysis in the second half of 2026 with possible sample‑size adjustment, expanding preeclampsia enrollment across Part 1a, 1b and 2 plus a 30‑patient early‑onset Phase II in Canada, initiating a fetal growth restriction cohort in the second quarter of 2026 and resolving the reproductive toxicology strategy.

DiaMedica’s earnings call painted a picture of a company making clear scientific and operational strides while navigating complex regulatory demands and rising costs. For investors, the story now hinges on whether promising preeclampsia data and a cleaner stroke safety profile can translate into value before cash burn and U.S. regulatory questions become more pressing constraints.